No abstract

Oncology Group performance status score of 0e1 (odds ratio [OR], 3.07; P ¼ 0.003) and no initial central nervous system (CNS) metastases (OR, 2.43; P ¼ 0.014) were independent predictors of PD in the initially involved sites alone. The 1e3 metastases at the start of EGFR-TKI treatment was not a predictor of PD in the initially involved sites alone (OR, 2.05; P ¼ 0.297). Multivariate logistic regression analyses of the clinical factors at 12 weeks from the start of EGFR-TKI treatment revealed that 1e3 residual metastases (OR, 3.07; P ¼ 0.003) and no residual CNS metastases (OR, 3.26; P ¼ 0.014) were independent predictors of PD in the initially involved sites alone. Additional multivariate logistic regression analyses of the clinical factors at 12 weeks from the start of EGFR-TKI treatment revealed that 1e3 residual metastases (OR, 3.18; P ¼ 0.002) and no residual CNS metastases (OR 2.77; P ¼ 0.026) were independent predictors of PD in residually involved sites alone. Conclusion: The results of this study showed that the initial 1e3 metastases at the start of EGFR-TKI treatment was not a predictor of PD in the initially involved sites alone, and that 1e3 residual metastases at 12 weeks from the start of EGFR-TKI treatment and no residual CNS metastases were independent predictors of PD in the residually involved sites alone in patients with EGFR-mutated NSCLC. Accordingly, the oligometastatic state at 12 weeks from the start of EGFR-TKI treatment might be a candidate for LAT to all sites of disease.